ES2178961A1 - Fabricacion de nanoparticulas a base del copolimero de metil vinil eter y anhidrido maleico para la administracion de farmacos de naturaleza hidrofilica, en particular de bases puricas y pirimidinicas. - Google Patents

Fabricacion de nanoparticulas a base del copolimero de metil vinil eter y anhidrido maleico para la administracion de farmacos de naturaleza hidrofilica, en particular de bases puricas y pirimidinicas.

Info

Publication number
ES2178961A1
ES2178961A1 ES200100530A ES200100530A ES2178961A1 ES 2178961 A1 ES2178961 A1 ES 2178961A1 ES 200100530 A ES200100530 A ES 200100530A ES 200100530 A ES200100530 A ES 200100530A ES 2178961 A1 ES2178961 A1 ES 2178961A1
Authority
ES
Spain
Prior art keywords
nanoparticles
maleic anhydride
vinyl ether
drug
puric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES200100530A
Other languages
English (en)
Other versions
ES2178961B1 (es
Inventor
Vila Pau Arbos
De La Quintana Marta Merodio
Hernandez Amaia Arnedo
Flamarique Felix Recarte
Omaecheverria Maria J Renedo
Garreta Juan M Irache
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Instituto Cientifico y Tecnologico de Navarra SA
Original Assignee
Instituto Cientifico y Tecnologico de Navarra SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instituto Cientifico y Tecnologico de Navarra SA filed Critical Instituto Cientifico y Tecnologico de Navarra SA
Priority to ES200100530A priority Critical patent/ES2178961B1/es
Priority to US10/467,983 priority patent/US20050079222A1/en
Priority to EP02708372A priority patent/EP1369110A1/en
Priority to PCT/ES2002/000098 priority patent/WO2002069938A1/es
Publication of ES2178961A1 publication Critical patent/ES2178961A1/es
Application granted granted Critical
Publication of ES2178961B1 publication Critical patent/ES2178961B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Fabricación de nanopartículas a base del copolímero de metil y vinil éter y anhídrido maleico para la administración de fármacos de naturaleza hidrofílica, en particular de bases púricas y pirimidínicas. Las nanopartículas se obtienen por desolvatación con una fase hidroalcohólica de una solución en acetona del copolímero de metil vinil éter y anhídrido maleico. Posteriormente, las partículas obtenidas se tratan con agentes reticulantes (diaminas o proteínas) con el fin de alargar su vida útil y, eventualmente, se incuban con un fármaco que será transportado en superficie. Las nanopartículas pueden llevar el fármaco también encapsulado que se añadiría entonces durante la desolvatación. En el caso de los conjugados nanopartículaligando, las nanopartículas previamente obtenidas y conteniendo en su interior el fármaco a transportar se incuban con el ligando o molécula que aportará la propiedad de reconocer de manera específica un determinado receptor del organismo. Estas formas farmacéuticas tienen como objetivo mejorar el transporte del fármaco o molécula biológicamente activa a su lugar de acción y/o absorción. Esta propiedad mejora la especificidad y eficacia de dichos fármacos.
ES200100530A 2001-03-06 2001-03-06 Fabricacion de nanoparticulas a base del copolimero de metil vinil eter y anhidrido maleico para la administracion de farmacos de naturaleza hidrofilica, en particular de bases puricas y pirimidinicas. Expired - Fee Related ES2178961B1 (es)

Priority Applications (4)

Application Number Priority Date Filing Date Title
ES200100530A ES2178961B1 (es) 2001-03-06 2001-03-06 Fabricacion de nanoparticulas a base del copolimero de metil vinil eter y anhidrido maleico para la administracion de farmacos de naturaleza hidrofilica, en particular de bases puricas y pirimidinicas.
US10/467,983 US20050079222A1 (en) 2001-03-06 2002-03-06 Production of nanoparticles from methyl vinyl ether and maleic anhydride for the administration of hydrophilic pharmaceuticals, more particularly of puric and pyrimidinic bases
EP02708372A EP1369110A1 (en) 2001-03-06 2002-03-06 Production of nanoparticles from methyl vinyl ether copolymer and maleic anhydride for the administration of hydrophilic pharmaceuticals, more particularly of puric and pyrimidinic bases
PCT/ES2002/000098 WO2002069938A1 (es) 2001-03-06 2002-03-06 Fabricacion de nanoparticulas a base del copolimero de metil vinil eter y anhidrido maleico para la administracion de farmacos de naturaleza hidrofilica, en particular de bases puricas y pirimidinicas

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200100530A ES2178961B1 (es) 2001-03-06 2001-03-06 Fabricacion de nanoparticulas a base del copolimero de metil vinil eter y anhidrido maleico para la administracion de farmacos de naturaleza hidrofilica, en particular de bases puricas y pirimidinicas.

Publications (2)

Publication Number Publication Date
ES2178961A1 true ES2178961A1 (es) 2003-01-01
ES2178961B1 ES2178961B1 (es) 2004-07-01

Family

ID=8496996

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200100530A Expired - Fee Related ES2178961B1 (es) 2001-03-06 2001-03-06 Fabricacion de nanoparticulas a base del copolimero de metil vinil eter y anhidrido maleico para la administracion de farmacos de naturaleza hidrofilica, en particular de bases puricas y pirimidinicas.

Country Status (4)

Country Link
US (1) US20050079222A1 (es)
EP (1) EP1369110A1 (es)
ES (1) ES2178961B1 (es)
WO (1) WO2002069938A1 (es)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2286951A1 (es) * 2006-05-26 2007-12-01 Instituto Cientifico Y Tecnologico De Navarra, S.A Nanoparticulas bioadhesivas para la administracion de moleculas biologicamente activas.
WO2009071730A1 (es) * 2007-12-07 2009-06-11 Consejo Superior De Investigaciones Cientificas Composición de gentamicina, un surfactante aniónico, y un copolímero

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2246694B1 (es) * 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Nanoparticulas pegiladas.
ES2246695B1 (es) * 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Composicion estimuladora de la respuesta inmunitaria que comprende nanoparticulas a base de un copolimero de metil vinil eter y anhidrido maleico.
ES2310122B1 (es) 2007-04-20 2009-10-30 Instituto Cientifico Y Tecnologico De Navarra, S.A Nanoparticulas que comprenden una ciclodextrina y una molecula biologicamente activa y sus aplicaciones.
ES2327375B1 (es) 2007-11-14 2010-08-05 Universidad Del Pais Vasco Empleo de microparticulas para su uso como vacunas y la liberacion de moleculas biologicamente activas.
WO2011139218A1 (en) * 2010-05-04 2011-11-10 General Electric Company Nucleic acid delivery vehicle uses thereof
EP2510930A1 (en) * 2011-04-15 2012-10-17 Bionanoplus, S.L. Nanoparticles comprising half esters of poly (methyl vinyl ether-co-maleic anhydride) and uses thereof
ES2369949B1 (es) 2011-05-19 2013-08-13 Universidade De Santiago De Compostela Microesferas poliméricas como adyuvantes en la producción de vacunas frente a parásitos escuticociliados de peces.
US20130004651A1 (en) * 2011-07-01 2013-01-03 Patty Fu-Giles Sustained drug release from body implants using nanoparticle-embedded polymeric coating materials
WO2017048707A1 (en) 2015-09-14 2017-03-23 Saudi Arabian Oil Company Pendant epoxide polymers and methods of treating subterranean formations
EP3350279B1 (en) * 2015-09-14 2020-04-01 Saudi Arabian Oil Company Maleic anhydride polymers and methods of treating subterranean formations
RU2628881C2 (ru) * 2015-12-17 2017-08-22 федеральное государственное автономное образовательное учреждение высшего образования "Московский физико-технический институт (государственный университет)" Гидролизуемая кислотой композиция, включающая частицы микрогеля, для доставки лекарств в живые организмы и способ ее получения
CN109906262A (zh) 2016-11-04 2019-06-18 沙特阿拉伯石油公司 用于封堵与凝固水泥接触的流动通道的组合物和方法
US10526458B1 (en) * 2018-12-18 2020-01-07 Saudi Arabian Oil Company Gellable, non-aqueous oil well treatment fluids comprising elastomeric maleic anhydride copolymers

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0275796A1 (fr) * 1986-12-31 1988-07-27 Centre National De La Recherche Scientifique Procédé de préparation de systèmes colloidaux dispersibles d'une substance, sous forme du nanoparticules
WO1995035101A1 (fr) * 1994-06-22 1995-12-28 Rhone-Poulenc Rorer S.A. Nanoparticules stabilisees et filtrables dans des conditions steriles

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU629316B2 (en) * 1990-04-11 1992-10-01 Flora Inc. Periodontal disease treatment system
US5562909A (en) * 1993-07-12 1996-10-08 Massachusetts Institute Of Technology Phosphazene polyelectrolytes as immunoadjuvants
FR2762394B1 (fr) * 1997-04-16 1999-05-28 Bio Merieux Compose ligand de coordination et utilisation pour fixer un materiel biologique
US6229009B1 (en) * 1997-08-29 2001-05-08 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Polycarboxylic based cross-linked copolymers
US7217735B1 (en) * 1999-04-09 2007-05-15 Au Jessie L-S Methods and compositions for enhancing delivery of therapeutic agents to tissues

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0275796A1 (fr) * 1986-12-31 1988-07-27 Centre National De La Recherche Scientifique Procédé de préparation de systèmes colloidaux dispersibles d'une substance, sous forme du nanoparticules
WO1995035101A1 (fr) * 1994-06-22 1995-12-28 Rhone-Poulenc Rorer S.A. Nanoparticules stabilisees et filtrables dans des conditions steriles

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ARNEDO, A. et al. "Determination of oligonucleotide ISIS 2922 in nanoparticlate delivery systems by capillary zone electrophoresis", Journal of Chromatography, A. Netherlands, 25 Feb. 2000, Volumen 871, Nö 1-2, páginas 311-320, (resumen) Medline (en línea) Bethesda, MD (EE.UU): Unites States National Library of Medicina [recuperado el 03.06.2002]. Recuperado de: EPO MEDLINE/NLM. Nö de acceso de Medline 10735311. *
MERODIO, M. et al. "Development of a sensitive method for the determination of ganciclovir by reversed-phase high-performance liquid chromatography", Journal of Chromatography, A. Netherlands, 18 Feb. 2000, Volumen 870, Nö 1-2, páginas 159-167, (resumen) Medline (en línea) Bethesda, MD (EE.UU): United States National Library of Medicina [recuperado el 03.06.2002]. Recuperado de: EPO MEDLINE/NLM. Nö de acceso de Medline 10722073. *
YALABIK-HAS, H.S. et al. "Sorption of 5-fluorouracil from aqueous solutions onto methyl methacrylate nanoparticles", Journal of Microencapsulation, England, Abr-Jun 1986, Volumen 3, Nö 2, páginas 71-75, (resumen). Medline (en línea) Bethesda, MD (EE.UU): United States National Library of Medicina [recuperado el 03.06.2002]. Recuperado de: EPO MEDLINE/NLM. Nö de acceso de Medline 3508180. *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2286951A1 (es) * 2006-05-26 2007-12-01 Instituto Cientifico Y Tecnologico De Navarra, S.A Nanoparticulas bioadhesivas para la administracion de moleculas biologicamente activas.
WO2007138135A1 (es) * 2006-05-26 2007-12-06 Instituto Científico Y Tecnológico De Navarra, S.A. Nanopartículas bioadhesivas para la administración de moléculas biológicamente activas
ES2286951B1 (es) * 2006-05-26 2008-10-01 Instituto Cientifico Y Tecnologico De Navarra, S.A Nanoparticulas bioadhesivas para la administracion de moleculas biologicamente activas.
WO2009071730A1 (es) * 2007-12-07 2009-06-11 Consejo Superior De Investigaciones Cientificas Composición de gentamicina, un surfactante aniónico, y un copolímero
ES2328001A1 (es) * 2007-12-07 2009-11-05 Consejo Superior De Investigaciones Cientificas (60%) Composicion de gentamicina, un surfactante anionico, y un copolimero.
ES2328001B1 (es) * 2007-12-07 2010-09-20 Consejo Superior De Investigaciones Cientificas (60%) Composicion de gentamicina, un surfactante anionico, y un copolimero.

Also Published As

Publication number Publication date
ES2178961B1 (es) 2004-07-01
EP1369110A1 (en) 2003-12-10
WO2002069938A1 (es) 2002-09-12
US20050079222A1 (en) 2005-04-14

Similar Documents

Publication Publication Date Title
ES2178961A1 (es) Fabricacion de nanoparticulas a base del copolimero de metil vinil eter y anhidrido maleico para la administracion de farmacos de naturaleza hidrofilica, en particular de bases puricas y pirimidinicas.
Shinde et al. Methotrexate: a gold standard for treatment of rheumatoid arthritis
DE60330322D1 (de) Arzneimittel-mikroteilchen
BRPI0416613A (pt) composição e forma de dosagem compreendendo uma molécula anfifìlica como um veìculo de suspensão
DE60315145D1 (de) Hydrophiles polymerderivat mit y-verzweigung und herstellungsverfahren dafür; obige verbindung enthaltender medizinischer verbundwerkstoff
CL2008003595A1 (es) Compuestos heterociclicos nitrogenados, antagonistas del receptor de taquiquinina; agente farmaceutico que comprende el compuesto; y uso en la profilaxis o el tratamiento de una enfermedad del tracto urinario inferior, una enfermedad gastrointestinal o una enfermedad del sistema nervioso central.
ATE356612T1 (de) Orale, pharmazeutische darreichungsformen von flüssigen medikamenten mitverbesserter bioverfügbarkeit
MXPA06012583A (es) Nanoparticulas pegiladas.
MXPA05003591A (es) Materiales basados en ciclodextrina, composiciones y usos relacionados a los mismos.
WO2007040469A3 (en) Chloroquine coupled compositions and methods for their synthesis
MD20070267A (en) Gastroresistant pharmaceutical formulation containing rifaximin
AR082579A2 (es) Una composicion farmaceutica espontaneamente dispersable para la administracion oral, uso para la preparacion de un medicamento para el tratamiento del cancer, metodo para incrementar los niveles de biodisponibilidad o reducir su variabilidad
TW200640498A (en) Suspending vehicles and pharmaceutical suspensions for drug dosage forms
ITMI20041317A1 (it) Formulazioni farmaceutiche per la somministrazione sicura di farmaci utilizzati nel trattamento della tossicodipendenza e procedimento per il loro ottenimento
PA8594801A1 (es) Formulaciones farmaceuticas liquidas de palanosetron
DE60327772D1 (de) Arzneimittel für die dickdarmverabreichung von wirkstoffen
ATE426635T1 (de) Arzneimittelverabreichung
UY27929A1 (es) Composiciones farmaceuticas de farmacos semiordenados y polimeros
Lim et al. Composing on-program triggers and on-demand stimuli into biosensor drug carriers in drug delivery systems for programmable arthritis therapy
ATE367803T1 (de) Subcutane implantate mit begrenzter initialer wirkstoff-freisetzung und deren anschliessende lineare veränderliche verlängerte freisetzung
DE60142913D1 (de) Arzneilösungen enthaltend modafinilverbindungen
AR048342A1 (es) FORMAS DE DOSIFICACIoN FARMACÉUTICAS QUE COMPRENDEN EL ÁCIDO N-(2-(2-FTALIMIDOETOXI)-ACETIL)-L-ALANIL-D-GLUTÁMICO (LK-423)
ATE447939T1 (de) Dosierungsformen enthaltend thyroidhormone und deren herstellungsverfahren
Mishra et al. Biomaterials for targeting endoplasmic reticulum in cancer
NO20076120L (no) Stabile nanopartikkelformuleringer

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20030101

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2178961B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20180807